Clinical Trial Update: Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other Diseases

View source ↗

Summary

A completed clinical trial update evaluating pulmonary physiology and systemic inflammatory responses associated with brigatinib use in non-small cell lung canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alunbrig (Brigatinib)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Non-Small Cell Lung Cancer | Status: COMPLETED